Hospitals can contract to have the services available to their patients on a rotating basis. This set up allows hospitals to provide the latest medical therapy, cost-effectively. In many instances, it provides a trial run to insure that they have the patient populations prior to committing to an actual purchase of the machine. BPH affects 9 million men over the age of 50 throughout the United States alone. The one-hour outpatient procedure requires only local anesthesia, and has virtually none of the risks or financial cost of surgical procedures.
Patients can resume normal activities immediately following treatment.
Due to strong patient demand, large institutions and university hospitals have been the first to acquire the Prostatron . Many leading centers such as Georgetown University Medical Center in Washington, DC, Long Island Jewish Hospital in New Hyde Park, NY, and Mt. Sinai Medical Center in Miami, Florida are already equipped, and attracting patients from far beyond their geographic region. Boston University Medical Center will soon be providing this new prostate therapy with the Prostatron . EDAP Technomed is an international company which is engaged in the development, manufacture and distribution of minimally invasive therapeutic devices for the treatment of urological diseases including kidney stone disease, BPH and cancer. EDAP Technomed, Inc. based in Cambridge, Mass., is the US distributor of the Prostatron .